Molecular Biomarker Testing for Noncancer Indications - MEDICAID - FLORIDA

Covers molecular biomarker testing for noncancer indications — e.g., APOL1 gene testing for chronic kidney disease and donor risk assessment, diagnostic and carrier testing for inherited disorders such as GM2 gangliosidoses (Tay‑Sachs/Sandhoff), and noninvasive prenatal screening/maternal serum marker screening. Major limitations: cancer indications are excluded, specific tests (notably some cardiac assays) are listed as excluded, pre‑ and post‑test genetic counseling is required, and coverage is subject to the member’s benefit document and periodic policy updates.

"Noncancer indications (implied by title: testing described is for noncancer indications)."

Sign up to see full coverage criteria, indications, and limitations.